@article{e7c827390e7e4c4983b621f97a34b156,
title = "Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae",
abstract = "Carbapenem-resistant Enterobacteriaceae (CRE) strains are an urgent public health threat. We evaluated the in vitro activities of 19 antimicrobial agents, including imipenem-relebactam, against (i) 106 CRE bloodstream isolates that primarily expressed Klebsiella pneumoniae carbapenemase (KPC) and (ii) 20 OXA-48-like-expressing CRE isolates. Ninety-five percent of CRE bloodstream isolates were susceptible to imipenem-relebactam. In contrast to their comparable activities against KPC-producing CRE strains, ceftazidime-avibactam was more active in vitro against OXA-48-like CRE strains than was imipenem-relebactam (90% susceptible versus 15% susceptible).",
keywords = "Carbapenem-resistant Enterobacteriaceae, Ceftazidime-avibactam, Imipenem-relebactam",
author = "Canver, {Matthew C.} and Satlin, {Michael J.} and Westblade, {Lars F.} and Kreiswirth, {Barry N.} and Liang Chen and Amy Robertson and Kathy Fauntleroy and Spina, {Marisa La} and Katrina Callan and Jenkins, {Stephen G.}",
note = "Funding Information: M.J.S. has received research grant funding from Merck and Co., Inc., and Allergan and has received consulting fees from Shionogi, Inc., and Achaogen. S.G.J. has received research grant funding from Merck and Co., Inc., and has received consulting fees from Shionogi, Inc. All other authors have no competing financial interests. Funding Information: This work was supported by an investigator-initiated grant provided by Merck and Co., Inc. M.J.S. has received research grant funding from Merck and Co., Inc., and Allergan and has received consulting fees from Shionogi, Inc., and Achaogen. S.G.J. has received research grant funding from Merck and Co., Inc., and has received consulting fees from Shionogi, Inc. All other authors have no competing financial interests. Funding Information: This work was supported by an investigator-initiated grant provided by Merck and Co., Inc. Publisher Copyright: Copyright {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved.",
year = "2019",
doi = "10.1128/AAC.00672-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",
}